Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario

•About 35% of localized RCC patients recur after nephrectomy.•A unique and universally accepted risk factor model is still missing.•VEGFR-TKIs failed in demonstrating a significant activity as adjuvant treatment.•Adjuvant pembrolizumab significantly prolongs the disease-free survival.•The efficacy o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2023-04, Vol.115, p.102528-102528, Article 102528
Hauptverfasser:	Ciccarese, Chiara, Strusi, Alessandro, Arduini, Daniela, Russo, Pierluigi, Palermo, Giuseppe, Foschi, Nazario, Racioppi, Marco, Tortora, Giampaolo, Iacovelli, Roberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant therapy Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - surgery Chemotherapy, Adjuvant Humans Immunotherapy Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Kidney Neoplasms - surgery M1NED Neoplasm Recurrence, Local - drug therapy Nephrectomy RCC Renal cell carcinoma Risk Assessment Risk factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!